Home » today » Technology » Technical News | Windows 10X might not arrive until 2021

Technical News | Windows 10X might not arrive until 2021

A vaccine against the coronavirus under development at the University of Oxford is safe and induces an immune response to the disease, the first phase of human trials has revealed.

Doses of the vaccine, called AZD1222, were given to 1,077 healthy adults aged 18 to 55 at five UK hospitals in April and May.

The results – published in the Lancet journal on Monday – show they elicited strong immune responses in antibodies and T cells for up to 56 days after administration.

video callfn" data-component-name="sdc-article-video" data-provider="ooyala" data-video-blacklisted-originator-ids="" data-video-id="5044999" data-sdc-video-id="g0ZG1rajE6eao_Dlz1BHqWHeBBHhECGi" data-package="" data-originator-id="37" data-fn="sdc-article-video" data-lite="true" data-role="roadblock-success" data-clip-type="" data-competition="" data-sport-category="" data-amp-iframe-embed="">



Could anti-vaxxers convince against vaccine?


T cells are essential to maintain protection against the virus for years to come.

Scientists have found that the response may be even greater after a second dose of the vaccine.

Compared to a control group, which received a meningitis vaccine, the COVID-19[feminine[feminine the vaccine had minor side effects more frequently, but these could be reduced by taking paracetamol. The vaccine did not reveal any serious side effects, according to the report.

The UK government has reached an agreement with AstraZeneca and the University of Oxford to secure access to 100 million doses of vaccine.

Professor Andrew Pollard, who is leading the study at the University of Oxford, said: “The immune system has two ways of finding and attacking pathogens – antibodies and T-cell responses.

“This vaccine is meant to induce both, so it can attack the virus as it travels through the body, as well as infected cells.

“We hope this means that the immune system will remember the virus, so our vaccine will protect people for an extended period.

“However, we need more research before we can confirm that the vaccine effectively protects against SARS-CoV-2 infection, and for how long any protection lasts. “

video callfn" data-component-name="sdc-article-video" data-provider="ooyala" data-video-blacklisted-originator-ids="" data-video-id="5041335" data-sdc-video-id="V4a2VrajE6YLh2WIj7JHFZ1JrlSe145d" data-package="" data-originator-id="37" data-fn="sdc-article-video" data-lite="true" data-role="roadblock-success" data-clip-type="" data-competition="" data-sport-category="" data-amp-iframe-embed="">



Russian spies try to steal vaccine research


The royal spoke to prominent scientists from the Oxford testing team
Image:
The Duke of Cambridge visited the University of Oxford team working on the COVID-19 vaccine last month

Professor Sarah Gilbert, co-author of the study, said: “There is still a lot of work to be done before we can confirm whether our vaccine will help manage the COVID-19 pandemic, but these early results are promising.

“In addition to continuing to test our vaccine in Phase 3 trials, we need to learn more about the virus – for example, we still don’t know how much of an immune response we need to effectively protect against infection. by SARS-CoV-2. .

“If our vaccine is effective, it is a promising option because these types of vaccines can be manufactured on a large scale. “

Although these results come from the first phase of the trials, phase two testing is already underway in the UK and phase three testing on volunteers in Brazil and South Africa is also underway.

AstraZeneca’s vaccine is one of several leading candidates around the world, including an injection under development by Sinovac Biotech in China, another from Chinese state-owned Sinopharm, and one from US biotech company Moderna. .

UK government also obtained early access to 90 million COVID-19 vaccine doses thanks to partnerships with pharmaceutical companies, including 30 million of one in development by BioNTech and Pfizer, and 60 million from Valneva which has a plant in Scotland.

“The Oxford University team leads the global race for a COVID-19 vaccine”

By Thomas Moore, scientific correspondent

The results of the first clinical trial of the COVID-19 vaccine under development by scientists at Oxford suggest that it triggers a strong double defense of the immune system.

Data from the Phase 1 safety study shows that the volunteers produced a significant increase in antibodies and killer T cells that help clear the infection from the body.

The antibodies were able to kill the virus in lab tests, an early indication that the vaccine is working.

More research will be needed to confirm whether the immune response is sufficient to protect people against COVID-19.

Research also shows that there have been no serious side effects.

Scientists at the Jenner Institute at Oxford University have already made progress towards Phase 3 studies of the vaccine in collaboration with pharmaceutical company AstraZeneca.

Several thousand volunteers in the UK, Brazil and South Africa receive the vaccine to test its effectiveness.

The team is leading the global race to develop a vaccine.

The UK government bought 100 million doses ahead of the results, with deliveries expected by the end of the year, if all goes well.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.